Welcome to 2nd Annual Metabolic Diseases World Summit

5:00 PM Registration

5:30 PM Opening Reception and Poster Session

Day Two: Friday, May 19, 2006

7:30 Breakfast and Registration

8:30 PLENARY KEYNOTE PRESENTATION

The Challenge of the Metabolic Syndrome
Dr. Doug Greene, Vice President, Product Development, Sanofi-Aventis


The Metabolic Syndrome & Diabetes
Treatment Targets for the Metabolic Syndrome

--Track 1--

9:40 Hypertension and the Metabolic Syndrome
David Bell, M.D, University of Alabama

10:15 Refreshment Break 10:15 Refreshment Break

10:45 GLP-1 and Incretin Mimetics in the
Management of Type 2 Diabetes
Dr. John Holcombe, Eli Lilly & Co.

11:20 Target Validation or Fool’s Gold
Peer Jacobson Ph.D, Dept of Metabolic Disease Research, Abbott Laboratories

11:55 Lunch & Poster Session

1:30 Vascular Biology of PPARs and SPPARMs
Ronald Law, Ph.D., J.D., Dir, Medical & Scientific Product Evaluation, Takeda Pharm

2:05 Pharmaceutical R&D Type II Diabetes
Richard Ho, Ph.D., Head, Medical Informatics, Johnson & Johnson

2:40 Refreshment Break

3:10 Molecular Activation of PPARg by Sartans
David Erbe, Ph.D., Cardiovascular and Metabolic Diseases, Wyeth Research

3:45 Inhibitors of 11β-HSD1 in Murine Models of Metabolic Syndrome, Atherosclerosis and Cognition
Rolf Thieringer, Ph.D., Cardiovascular Diseases, Merck Research Laboratories

4:20 Ligands to Peroxisome Proliferator-Activated Receptors as Therapeutic Targets for Type 2 Diabetes and the Metabolic Syndrome
Anne Reifel Miller, Chief Scientific Officer, Diabetes Research Div, Eli Lilly & Co.

4:55 PTP1B and Diabetes
Robert Mashal, M.D, Alinea Pharmaceuticals

5:30 End of Day 2

--Track 2--

9:40 Steroids and the Metabolic Syndrome
Bernice Welles, M.D., Vice President, Development, Diobex Inc.

10:15 Refreshment Break 10:15 Refreshment Break

10:45 11-beta-HSD1 Ming Wang, Ph.D., Metabolic Disorders, Amgen Inc.

11:20 Propiomelanocortin Analogues John Mayer, Ph..D., Eli Lilly & Co.

11:55 Lunch & Poster Session

1:30 New Approaches to Hyperlipidemia
Te Yuan Kiu, M.D., Pfizer, Inc.

2:05 Hypogonadism and the Metabolic Syndrome – Lessons from Clinical Studies John Rodzvilla, M.D., Auxilium Pharmaceuticals

2:40 Refreshment Break

3:10 PPAR: A New Target to Treat the Metabolic Syndrome
Grant Barish, M.D., Salk Institute for
Biomedical Research

3:45 Neuromedin Receptors and Obesity
Lori Gowen Morton, Ph.D., Staff Scientist,
Regeneron Pharmaceuticals

4:20 RNAi Screens Drive the Discovery & Development of Molecular Based Medicines to Treat Diabetes and Obesity
Harold M. Wright, Ph.D., Director of Biology,
CytRx Corporation

5:30 End of Day 2

Day Three: Saturday, May 20, 2006


8:15 Registration & Breakfast
The Metabolic Syndrome in Our Practice

9:00 The Clinician Faces the Metabolic Syndrome
Dan Einhorn, M.D., Scripps Whittier Diabetes Institute

9:35 Our Children and the Metabolic Syndrome
Jean Claude Desmangles, Creighton University

10:10 Refreshment Break

10:40 The Metabolic Syndrome and Pregnancy
Lois Jovanovic, M.D., Sansum Research Institute

11:15 Insulin Resistance and The Metabolic Syndrome
John Gerich, M.D, The University of Rochester

11:50 PANEL DISCUSSION: What Should We Do About the Metabolic Syndrome?
Dan Einhorn, M.D., Scripps Whittier Diabetes Institute
Jean Claude Desmangles, Creighton University
Lois Jovanovic, M.D., Sansum Research Institute
John Gerich, M.D, The University of Rochester

12:50 Lunch
The Metabolic Syndrome and Cardiovascular Disease

2:30 The Endothelium in Metabolic Syndrome
Paresh Dandona, M.D., University of Buffalo

3:05 The Role of Aldosterone in Cardiovascular Disease
Marcia Heron, Ph.D., Pfizer Inc

3:40 Refreshment Break

4:10 Heart Disease in Women
Joel Ray, M.D., University of Toronto

4:45 Hyperlipidemia, Renal Disease, and the Metabolic Syndrome
Daniel Wilson, M.D., Pfizer Inc

5:20 End of Day 3

Day Four: Sunday, May 21, 2006


7:15 Registration & Breakfast
Business Session - Drug Developments: More Than Discovery

8:00 Investment Opportunities in the Metabolic Syndrome
TBD

8:45 Partnering Trends and Opportunities in Metabolic Diseases
Wick Johnson, Pfizer Inc

9:30 Establishing High-Value Alliances
Linda Egger, Merck and Company

10:15 Refreshment Break

10:45 Challenges for Metabolic Disease Deal-Making: Assessing Risk and Opportunity
Tim Duffy, EVP, Marketing & Business Development, Nastech Pharmaceutical Co.

11:30 Assessing the Patent Environment in Metabolic Diseases
Ralph A. Loren, Senior Counsel, Edwards Angell Palmer & Dodge LLP

12:15 Opportunities to Partner with National Institute of Diabetes & Digestive & Kidney Diseases
TBD

1:00 Conference Conclusion
Sponsorships & Exhibition Opportunities Available
Call 626-256-6405 for More Details

Peer Jacobson, PhD
Project Leader, Metabolic Disease Research, Abbott Laboratories

Ming Wang, PhD
Department of Metabolic Disorders, Amgen Inc.

David Erbe, PhD
Cardiovascular and Metabolic Diseases, Wyeth Research

Joseph S. Grimsby, Ph.D.
Sr. Research Leader, Metabolic Diseases, Hoffmann-La Roche

Linda Egger, PhD
Assoc Director, Scientific Liaison, External Scientific Affairs, Merck & Co., Inc.

Dr. Doug Greene
Vice President, Product Development, Sanofi Aventis

Te Yuan Kiu, MD
Pfizer, Inc.

Dan Einhorn
Head, Scripps Whittier Diabetes Institute

John Gerich, MD
Clinical Research Center, University of Rochester School of Medicine

Aaron Vinik, MD, PhD
Director of Research, Strelitz Diabetes Institutes, University of Eastern Virginia

Paresh Dandona, MD
Professor of Medicine, University of Buffalo

David Bell, MD
Endocrinologist, University of Alabama at Birmingham School of Medicine

Grant Barish, MD
Howard Hughes Medical Institute and Gene Expression Laboratory, The Salk Institute for Biological Studies

Bernice Welles, MD, MBA
Vice President, Development, DiObex

Tian-Li Yue, PhD
Manager, Investigative & Cardiac Biology, GlaxoSmithKline

Scott Braunstein
JP Morgan

Lois Jovanovic
Sansum Diabetes Research Institute

Wick Johnson, Ph.D.
Director, Licensing & Development, Pfizer Inc

John P. Mayer, PhD
Eli Lilly & Co.

Jean Claude Desmangles
Creighton University

Rolf Thierringer
Department of Cardiovascular Diseases, Merck Research Laboratories

Robert Mashal
President & CEO, Alinea Pharmaceuticals

Joel G Ray, MD MSc FRCPC
Assist Prof & Clinician Scientist, Dept of Med, Div of Endocrinology and Metabolism, University of Toronto

John Holcombe, MD
Medical Fellow, US Diabetes Care, Eli Lilly & Co.

CONFERENCE CHAIRPERSON
Marc Rendell, MD
Creighton University

Lori Gowen Morton
Staff Scientist, Regeneron Pharmaceuticals

Ronald E. Law, PhD, JD
Director, Medical and Scientific Product Evaluation, Takeda Pharmaceuticals North America

John Rodzvilla, MD
Auxilium Pharmaceuticals

Sanjay Bhanot, MD, PhD
Vice President, Metabolic Diseases Research & Development, Isis Pharmaceuticals

Harold Wright
Director, Biology, CytRx Corp

Daniel J. Wilson, MD
Director, Regional Medical Research Specialist Cardiovascular - Midwest, Pfizer Inc.

Commercial - $1595.00
Academic/Gov - $695.00
Student - $595.00

Early registration discount

60 days prior to conference start date: 20% discount with pre-payment
30 days prior to conference start date: 10% discount with prepayment